Clinical Trials Browser

Active not recruiting × Recurrence × 90 days × Clear all

NCT02491632 2026-03-18

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

Phase 2/3 Active not recruiting

90 enrolled 13 charts

Fatigue, Neoplasm Metastasis, Neoplasms, Recurrence

NCT03021486 2026-03-18

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

Phase 2/3 Active not recruiting

70 enrolled 20 charts

Delirium, Neoplasm Metastasis, Recurrence

NCT05552976 2026-03-17

SUCCESSOR-2

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT03742245 2026-03-16

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT05784441 2026-03-13

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Phase 1 Active not recruiting

Recurrence, Lymphoma, B-Cell

NCT06425991 2026-03-13

MajesTEC-10

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT04416984 2026-03-04

ALPHA2

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Phase 2 Active not recruiting

Recurrence

NCT06846606 2026-03-03

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT06984328 2026-03-03

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Phase 2 Active not recruiting

Melanoma, Recurrence

NCT05815160 2026-02-27

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Phase 1 Active not recruiting

Recurrence, Small Cell Lung Carcinoma

NCT04279847 2026-02-25

LIMBER

Phase 1 Active not recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05537740 2026-02-23

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT05527184 2026-02-20

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Phase 1 Active not recruiting

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Recurrence, Endometrial Neoplasms

NCT05888493 2026-02-20

LEDA

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT03930953 2026-02-19

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin, Recurrence

NCT04842877 2026-02-19

Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Phase 2 Active not recruiting

Recurrence, Lymphoma, B-Cell

NCT05144841 2026-02-13

MK-2140-004

Phase 2 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05572515 2026-02-13

MajesTEC-9

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2 Active not recruiting

Breast Neoplasms, Recurrence

NCT06024603 2026-02-12

Individualized Treatments in Adults With Relapsed/Refractory Cancers

Phase NA Active not recruiting

Neoplasms, Recurrence

NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT04155749 2026-02-11

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04690595 2026-02-11

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

Phase 1 Active not recruiting

Burkitt Lymphoma, Recurrence

NCT07391137 2026-02-09

CRUCIAL-R

Phase NA Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Recurrence

NCT05126719 2026-02-06

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma, Recurrence

NCT06097364 2026-02-06

OLYMPIA-2

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT06485219 2026-02-06

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Phase 2 Active not recruiting

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT07393204 2026-02-06

EPKEY_HSR

Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06880549 2026-02-05

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

Phase 1 Active not recruiting

Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT04712097 2026-02-04

Celestimo

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT05460533 2026-02-04

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

Phase 2 Active not recruiting

Burkitt Lymphoma, Recurrence

NCT07387874 2026-02-04

A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors

Active not recruiting

Recurrence

NCT02651662 2026-02-02

CLIO-1

Phase 1 Active not recruiting

Recurrence, Lymphoma, B-Cell

NCT05043922 2026-01-30

A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

Phase 2 Active not recruiting

Ovarian Neoplasms, Recurrence

NCT05797246 2026-01-26

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

Phase 2 Active not recruiting

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT06359002 2026-01-20

Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

Phase 1 Active not recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05455320 2026-01-16

MonumenTAL-3

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT06768476 2026-01-16

AML

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT01562405 2026-01-14

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT04656535 2026-01-07

AB154 Combined With AB122 for Recurrent Glioblastoma

Phase EARLY_PHASE1 Active not recruiting

Glioblastoma, Recurrence

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Phase 2/3 Active not recruiting

289 enrolled 35 charts 1 FDA

Myelodysplastic Syndromes, Recurrence

NCT05199051 2026-01-05

AGORA-1

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT02286687 2026-01-02

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Phase 2 Active not recruiting

Neoplasm Metastasis, Neoplasms, Recurrence

NCT03743649 2025-12-26

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Phase 2/3 Active not recruiting

Delirium, Neoplasm Metastasis, Recurrence

NCT02650401 2025-12-24

STARTRK-NG

Phase 1/2 Active not recruiting

69 enrolled 1 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic